Ambien (zolpidem) is a sedative-hypnotic, a class of drugs designed to induce and maintain sleep. It’s specifically categorized as a non-benzodiazepine hypnotic, meaning it produces calming, sleep-promoting effects similar to benzodiazepines like Valium or Xanax but belongs to a different chemical family. The U.S. Drug Enforcement Administration classifies Ambien as a Schedule IV controlled substance, a category reserved for drugs with a low potential for abuse and a low risk of dependence.
How Ambien Differs From Benzodiazepines
Ambien works on the same general target in the brain as benzodiazepines: the GABA-A receptor, which is the main receptor responsible for calming neural activity. Both drugs enhance the effect of GABA, your brain’s primary “slow down” chemical signal. The key difference is selectivity. Benzodiazepines bind broadly across several subtypes of this receptor, which is why they affect sleep, anxiety, muscle tension, and seizure activity all at once.
Zolpidem is far more selective. It binds with high affinity to receptors containing a specific subunit (called alpha-1) that is most closely tied to sedation and sleep. It has very low affinity for the receptor subtypes involved in anxiety relief and muscle relaxation, and essentially no effect on yet another subtype. This narrower targeting is why Ambien was initially thought to carry fewer side effects and less dependence risk than older benzodiazepines, though real-world experience has shown the picture is more complicated than that.
What Ambien Is Approved to Treat
The FDA approves Ambien for the short-term treatment of insomnia. The standard immediate-release tablet (brand name Ambien) is designed to help you fall asleep. The extended-release version (Ambien CR) has a two-layer design: one layer dissolves quickly to help with sleep onset, and a second layer releases the drug more slowly to help you stay asleep through the night. Ambien CR is specifically indicated for insomnia involving both difficulty falling asleep and difficulty staying asleep.
Beyond these oral tablets, zolpidem is also available as a sublingual tablet (Edluar) that dissolves under the tongue and an oral spray (Zolpimist). A lower-dose sublingual tablet (Intermezzo) was designed specifically for middle-of-the-night awakenings.
How Long It Lasts in Your Body
Ambien is a short-acting drug. The immediate-release version has an average half-life of about 2.2 hours in healthy adults, meaning half the drug is cleared from your system in roughly that time. The extended-release version has a slightly longer half-life of around 2.8 hours. In clinical trials, Ambien CR reduced nighttime wakefulness for up to seven hours during the first couple of nights and for about five hours after two weeks of regular use.
Despite its short half-life, the drug can impair you the next morning. This is especially true with the extended-release form. The FDA warns that patients can experience reduced mental alertness the morning after taking Ambien, even when they feel fully awake. This matters for driving, operating machinery, or anything requiring sharp focus early in the day.
Dosing Differences Between Women and Men
In 2013, the FDA took the unusual step of recommending different starting doses for women and men. Women clear zolpidem from their bodies more slowly, which means higher levels of the drug can still be circulating the next morning. For the immediate-release version, the recommended starting dose for women is 5 mg, while men can start at either 5 or 10 mg. For the extended-release version, women start at 6.25 mg; men can start at 6.25 or 12.5 mg. All doses are taken once, immediately before bedtime.
Complex Sleep Behaviors
Ambien carries an FDA boxed warning, the most serious type of safety alert, for the risk of complex sleep behaviors. These are activities people perform while not fully awake and typically have no memory of afterward. They include sleepwalking, sleep-driving, making phone calls, preparing food, and having conversations. While these events are rare, they have resulted in serious injuries and, in some cases, deaths. The FDA’s warning applies to anyone who has experienced even one episode: the recommendation is to stop taking the medication.
Why It’s a Controlled Substance
Ambien’s Schedule IV classification reflects the federal government’s assessment that it carries some risk of abuse and physical dependence, though less than drugs in higher schedules. In practice, dependence can develop when the drug is used nightly for more than a few weeks. People who stop abruptly after regular use may experience rebound insomnia, where sleep difficulty temporarily worsens beyond what it was before starting the medication. Tolerance, needing a higher dose to get the same effect, is also possible with prolonged use. This is one reason the FDA approval specifies short-term treatment rather than ongoing nightly use.